Patents by Inventor Torry A. TUCKER

Torry A. TUCKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form ? inhibitors
    Patent number: 12083098
    Abstract: Pharmaceutical compositions and methods are described which rely upon glycogen synthase kinase 3 (form ?; GSK 3 ?) inhibitors, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo including proliferation and differentiation of myofibroblasts to fibrotic fibroblasts in several mouse models. Therapeutic targeting of GSK-3? with the clinically useful specific inhibitor, 9-ING-41, mitigates fibrotic pulmonary remodeling in vivo and provides a mode of therapy of human IPF by specific GSK-3? inhibition with 9-ING-41.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: September 10, 2024
    Assignee: ACTUATE THERAPEUTICS INC.
    Inventors: Torry A. Tucker, Steven Idell
  • TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH GLYCOGEN SYNTHASE KINASE 3 FORM BETA INHIBITORS
    Publication number: 20210212988
    Abstract: Pharmaceutical compositions and methods are described which rely upon glycogen synthase kinase 3 (form ?; GSK 3?) inhibitors, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo including proliferation and differentiation of myofibroblasts to fibrotic fibroblasts in several mouse models. Therapeutic targeting of GSK-3? with the clinically useful specific inhibitor, 9-ING-41, mitigates fibrotic pulmonary remodeling in vivo and provides a mode of therapy of human IPF by specific GSK-3? inhibition with 9-ING-41.
    Type: Application
    Filed: May 16, 2019
    Publication date: July 15, 2021
    Inventors: Torry A. TUCKER, Steven IDELL